Anonymous
Guest
Anonymous
Guest
UPDATE: Novartis Touches New Year High - Posts Positive Results for Acute Heart Failure Treatment TrialBY Midnight Trader
— 10:41 AM ET 09/24/2012
10:41 AM EDT, 09/24/2012 (MidnightTrader) -- Novartis AG (NVS
Loading...
NVS is steady higher, up 0.20% to $61.37 after reaching a new 52-week high of $61.43. The healthcare solutions provide earlier reported positive results from its Phase III study to determine the efficacy and safety of the investigational compound RLX030, a recombinant form of the human hormone relaxin-2, in treating acute heart failure.
The results, which will be presented at the American Heart Association congress in Los Angeles in November, 2012, demonstrated that RLX030 reduced the number of deaths in patients with acute heart failure.
Price: 61.37, Change: +0.12, Percent Change: +0.20
http://www.midnighttrader.com
— 10:41 AM ET 09/24/2012
10:41 AM EDT, 09/24/2012 (MidnightTrader) -- Novartis AG (NVS
Loading...
NVS is steady higher, up 0.20% to $61.37 after reaching a new 52-week high of $61.43. The healthcare solutions provide earlier reported positive results from its Phase III study to determine the efficacy and safety of the investigational compound RLX030, a recombinant form of the human hormone relaxin-2, in treating acute heart failure.
The results, which will be presented at the American Heart Association congress in Los Angeles in November, 2012, demonstrated that RLX030 reduced the number of deaths in patients with acute heart failure.
Price: 61.37, Change: +0.12, Percent Change: +0.20
http://www.midnighttrader.com